-DOCSTART- -X- O
Here -X- _ O
, -X- _ O
we -X- _ O
report -X- _ O
a -X- _ O
cationic -X- _ B-Intervention
nanolipoplex -X- _ I-Intervention
as -X- _ O
a -X- _ O
pulmonary -X- _ O
cellular -X- _ O
delivery -X- _ O
system -X- _ O
for -X- _ O
small- -X- _ O
interfering -X- _ O
RNA -X- _ O
( -X- _ O
siRNA -X- _ O
) -X- _ O
. -X- _ O
Six -X- _ B-Intervention
nanoliposomes -X- _ I-Intervention
differing -X- _ O
in -X- _ O
cationic -X- _ O
lipids -X- _ O
were -X- _ O
formulated -X- _ O
and -X- _ O
screened -X- _ O
in -X- _ O
vitro -X- _ O
and -X- _ O
in -X- _ O
vivo -X- _ O
for -X- _ O
cellular -X- _ O
delivery -X- _ O
functions -X- _ O
in -X- _ O
lung -X- _ O
cells -X- _ O
/ -X- _ O
tissues. -X- _ O
Although -X- _ O
the -X- _ O
six -X- _ B-Intervention
nanoliposomes -X- _ I-Intervention
showed -X- _ O
similar -X- _ B-Outcome
siRNA -X- _ I-Outcome
delivery -X- _ I-Outcome
efficiency -X- _ I-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
, -X- _ I-Outcome
they -X- _ I-Outcome
exhibited -X- _ I-Outcome
significant -X- _ I-Outcome
differences -X- _ I-Outcome
in -X- _ I-Outcome
pulmonary -X- _ I-Outcome
cellular -X- _ I-Outcome
delivery -X- _ I-Outcome
functions -X- _ I-Outcome
in -X- _ I-Outcome
vivo. -X- _ I-Outcome
Among -X- _ I-Outcome
the -X- _ I-Outcome
various -X- _ I-Outcome
nanoliposomes -X- _ I-Outcome
, -X- _ I-Outcome
cationic -X- _ I-Outcome
dioleoyl-sn-glycero-3-ethylphosphocholine -X- _ I-Outcome
and -X- _ I-Outcome
cholesterol -X- _ I-Outcome
( -X- _ I-Outcome
ECL -X- _ I-Outcome
) -X- _ I-Outcome
-based -X- _ I-Outcome
nanoliposomes -X- _ I-Outcome
showed -X- _ I-Outcome
the -X- _ I-Outcome
highest -X- _ I-Outcome
pulmonary -X- _ I-Outcome
cellular -X- _ I-Outcome
delivery -X- _ I-Outcome
in -X- _ I-Outcome
vivo -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
lowest -X- _ I-Outcome
cytotoxicity -X- _ I-Outcome
in -X- _ I-Outcome
vitro. -X- _ I-Outcome
The -X- _ I-Outcome
delivery -X- _ I-Outcome
efficiency -X- _ I-Outcome
of -X- _ I-Outcome
fluorescent -X- _ I-Outcome
siRNA -X- _ I-Outcome
in -X- _ I-Outcome
ECL -X- _ I-Outcome
nanoliposomes -X- _ I-Outcome
was -X- _ I-Outcome
26.2-fold -X- _ I-Outcome
higher -X- _ I-Outcome
than -X- _ I-Outcome
that -X- _ I-Outcome
of -X- _ I-Outcome
naked -X- _ I-Outcome
siRNA -X- _ I-Outcome
in -X- _ I-Outcome
vivo. -X- _ I-Outcome
Treatment -X- _ I-Outcome
with -X- _ I-Outcome
Mcl1 -X- _ I-Outcome
( -X- _ I-Outcome
myeloid -X- _ I-Outcome
cell -X- _ I-Outcome
leukemia -X- _ I-Outcome
sequence -X- _ I-Outcome
1 -X- _ I-Outcome
) -X- _ I-Outcome
-specific -X- _ I-Outcome
siRNA -X- _ I-Outcome
( -X- _ I-Outcome
siMcl1 -X- _ I-Outcome
) -X- _ I-Outcome
using -X- _ I-Outcome
ECL -X- _ I-Outcome
nanolipoplexes -X- _ I-Outcome
reduced -X- _ I-Outcome
target -X- _ I-Outcome
expression -X- _ I-Outcome
in -X- _ I-Outcome
B16F10 -X- _ I-Outcome
cell -X- _ I-Outcome
lines -X- _ I-Outcome
, -X- _ I-Outcome
whereas -X- _ I-Outcome
control -X- _ I-Outcome
, -X- _ I-Outcome
luciferase-specific -X- _ I-Outcome
siGL2 -X- _ I-Outcome
in -X- _ I-Outcome
ECL -X- _ I-Outcome
nanolipoplexes -X- _ I-Outcome
did -X- _ I-Outcome
not. -X- _ I-Outcome
In -X- _ I-Outcome
metastatic -X- _ I-Outcome
lung -X- _ I-Outcome
cancer -X- _ I-Outcome
mouse -X- _ I-Outcome
models -X- _ I-Outcome
induced -X- _ I-Outcome
by -X- _ I-Outcome
B16F10 -X- _ I-Outcome
or -X- _ I-Outcome
Lewis -X- _ I-Outcome
lung -X- _ I-Outcome
carcinoma -X- _ I-Outcome
( -X- _ I-Outcome
LLC -X- _ I-Outcome
) -X- _ I-Outcome
cells -X- _ I-Outcome
, -X- _ I-Outcome
intratracheal -X- _ I-Outcome
administration -X- _ I-Outcome
of -X- _ I-Outcome
siMcl1 -X- _ I-Outcome
in -X- _ I-Outcome
ECL -X- _ I-Outcome
nanolipoplexes -X- _ I-Outcome
significantly -X- _ I-Outcome
silenced -X- _ I-Outcome
Mcl1 -X- _ I-Outcome
mRNA -X- _ I-Outcome
and -X- _ I-Outcome
protein -X- _ I-Outcome
levels -X- _ I-Outcome
in -X- _ I-Outcome
lung -X- _ I-Outcome
tissue. -X- _ I-Outcome
Reduced -X- _ I-Outcome
formation -X- _ I-Outcome
of -X- _ I-Outcome
melanoma -X- _ I-Outcome
tumor -X- _ I-Outcome
nodules -X- _ I-Outcome
was -X- _ I-Outcome
observed -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
lung. -X- _ I-Outcome
These -X- _ O
results -X- _ O
demonstrate -X- _ O
the -X- _ O
utility -X- _ O
of -X- _ O
ECL -X- _ B-Intervention
nanoliposomes -X- _ I-Intervention
for -X- _ O
pulmonary -X- _ O
delivery -X- _ O
of -X- _ O
therapeutic -X- _ O
siRNA -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
lung -X- _ B-Patient
cancers -X- _ I-Patient
and -X- _ I-Patient
potentially -X- _ I-Patient
for -X- _ I-Patient
other -X- _ I-Patient
respiratory -X- _ I-Patient
diseases -X- _ I-Patient
. -X- _ O

